249 related articles for article (PubMed ID: 7046930)
1. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Essential thrombocythemia following polycythemia vera: an unusual sequence.
Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative diseases.
Silverstein MN
Postgrad Med; 1977 Feb; 61(2):206-10. PubMed ID: 556856
[TBL] [Abstract][Full Text] [Related]
5. The effect of different doses of 32P in the treatment of primary thrombocytosis.
Randi ML; Fabris F; Varotto L; Peverelli P; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):950-6. PubMed ID: 2419226
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon in polycythemia vera and essential thrombocythemia.
Turri D; Mitra ME; Di Trapani R; Lipari MG; Perricone R; Cajozzo A
Haematologica; 1991; 76(1):75-7. PubMed ID: 2055565
[TBL] [Abstract][Full Text] [Related]
8. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
9. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the myeloproliferative disorders with 32P.
Berlin NI
Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of myeloproliferative syndromes].
Maurice P
Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
13. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
14. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
[TBL] [Abstract][Full Text] [Related]
15. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
16. Primary thrombocythemia.
Jamshidi K; Ansari A; Windschitl HE; Swaim WR
Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
[No Abstract] [Full Text] [Related]
17. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
Dingli D; Tefferi A
Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
[TBL] [Abstract][Full Text] [Related]
19. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR
N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681
[TBL] [Abstract][Full Text] [Related]
20. Observations on polycythemia vera turning into acute or chronic granulocytic leukemia during treatment with radioactive phosphorus 32P.
Krańik W
Pol Med Sci Hist Bull (1973); 1975; 15(4):447-52. PubMed ID: 1063385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
